Skip to content
n:ews

Category: Health

Health Policy shift

UnitedHealth and Humana Slide After CMS Proposes Wider Medicare Advantage Audits

UnitedHealth fell about 5.4% and Humana about 4% after CMS proposed wider Medicare Advantage audits, according to several outlets. The proposal would extrapolate audit findings from a sample across a whole contract, starting with payment year 2018, and CMS estimates it would recover about $9 billion per payment year. Public comments are due Jan. 19, 2027. Reported moves and dates vary by source.

Health Corporate action

CVS Plans to Split Pharmacies From Insurance in $117 Billion Breakup

CVS Health plans to split into two public companies, separating its retail pharmacies from its Aetna insurance and Caremark pharmacy-benefit businesses. The drugstore arm, including the stores, mail-order pharmacy and MinuteClinic, would become CVS Pharmacy in the first half of 2028 under Prem Shah. The rest stays as CVS Health, led by David Joyner, along with Oak Street Health and Signify Health.

Health Corporate action

Dermatology Biotech Bambusa Slides After $168.9 Million IPO

Bambusa Therapeutics raised $168.9 million in an upsized US initial public offering, pricing 10.6 million shares at $16, the midpoint of its range. The stock opened at $14.88, about 7% below the offer price, for a market value near $758 million. The Nasdaq-listed company develops bispecific antibodies for immunology and inflammation, led by a candidate for atopic dermatitis.

Health Company signal

Stryker Cuts Outlook as Cyberattack Impact on Supply Lingers

Stryker lowered its 2026 forecast, now expecting organic sales growth of 6.5% to 7% versus as much as 9.3% previously, and adjusted earnings of $14.80 to $14.90 a share. Third-quarter adjusted earnings of $3.52 a share on $6.5 billion of revenue missed estimates. The company said recovery from the March cyberattack is taking longer than expected, and hip and knee demand also slowed.

Health Company signal

Genmab Adds Over $10 Billion in Value on Cancer Drug Trial Wins

Genmab shares jumped about 30% on Oct. 28 after a late-stage trial of its drug petosemtamab combined with Keytruda showed a survival benefit in head and neck cancer. The stock has added more than $10 billion in market value this week to trade at a record, following earlier positive trial readouts in ovarian cancer and lymphoma. JPMorgan upgraded the shares to overweight.

Health Regional risk

Kenya Records Second Ebola Death as Uganda Restricts Transit

Kenya reported its second Ebola death, a 65-year-old woman who was a close relative of the first case and developed symptoms in quarantine. The country has nine confirmed cases, all in one cluster, with 135 contacts quarantined and no evidence of community spread, authorities said. Uganda said it will bar travellers with a history of travel to the Democratic Republic of Congo from transiting through the country.